Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/treatment-of-vulvovaginal-atrophy-uMnWit2VSO
References (7)
-
D. Portman, M. Gass (2014)
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause SocietyMenopause, 21
-
Prasterone (Intrarosa) for dyspareunia.
Med Lett Drugs Ther, 59
-
J. Simon, L. Nachtigall, L. Ulrich, M. Eugster-Hausmann, R. Gut (2010)
Endometrial Safety of Ultra-Low-Dose Estradiol Vaginal TabletsObstetrics & Gynecology, 116
-
(2018)
Imvexxy--another estradiol vaginal insert for dyspareunia.The Medical letter on drugs and therapeutics, 60 1555
-
R. Hayes, Michele Birch (2019)
Prasterone (Intrarosa) for Dyspareunia.American family physician, 99 2
-
J. Rioux, Corinne Devlin, M. Gelfand, W. Steinberg, D. Hepburn (2000)
17&bgr;‐Estradiol Vaginal Tablet Versus Conjugated Equine Estrogen Vaginal Cream to Relieve Menopausal Atrophic VaginitisMenopause, 7
-
C. Crandall, K. Hovey, C. Andrews, R. Chlebowski, M. Stefanick, D. Lane, J. Shifren, Chu Chen, A. Kaunitz, J. Cauley, J. Manson (2017)
Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational StudyMenopause, 25
- Publisher
- American Medical Association
- Copyright
- Copyright 2019 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2019.15100
- Publisher site
- See Article on Publisher Site
Abstract
This JAMA Insights Clinical Update discusses management options for women with vulvovaginal atrophy, focusing on the systemic safety of estrogen-based therapies and shared decision-making based on preference, cost, and adverse effect profile.
Journal
JAMA – American Medical Association
Published: Nov 19, 2019